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Background
The P2X7 receptor is a ligand-gated ion channel expressed
in neuronal, glial and immune cells and is implicated in a
wide range of pathological conditions, including
ischemia, and inflammation. The P2X7 receptor can mod-
ulate the maturation and release of the proinflammatory
cytokine, interleukin-1β (IL-1β). IL-1β is suggested to be
involved in the pathophysiology of depression and sick-
ness behaviour, elicited by peripherally administered bac-
terial lipopolysaccharide (LPS).
Methods
The levels of IL-1β production were quantified in the hip-
pocampi of rodents, using an ELISA kit. In order to iden-
tify genes involved in LPS-induced changes in P2X7
receptor knock-out (KO) and wild-type (WT) mouse amy-
gdala we performed whole mouse genome microarray
analysis of mRNA extracted after six hours of intaperito-
neal LPS injection.
Results
We showed that in vivo LPS challenge elevated IL-1β levels
in the rodent hippocampus. Antagonists of P2X receptors
inhibited LPS-induced IL-1β levels with a pharmacologi-
cal profile similar to that of P2X7 receptors and their
inhibitory effect was attenuated in the absence of P2X7
receptors. In WT mice, LPS overexpressed mRNA encoding
P2X4 and P2X7 receptors in the hippocampus and also
caused a remarkable increase in the levels of IL-1β in the
blood serum. The hippocampal increase of IL-1β was sub-
stantially alleviated when contamination by circulating
blood cells was excluded by transcardial perfusion, indi-
cating the peripheral origin of hippocampal IL-1β eleva-
tion. Six h after i.p. injection of LPS, the expression of 74
transcripts (41 upregulated and 33 downregulated) was
significantly altered two-fold or more in mouse amygdala.
These genes can be classified according to their biological
function as follows: inflammatory response: Il4ra,
Ccl21b; depression-associated genes: Slc17a7, Nfatc1,
Creb3l3. Our microarray studies have identified 8,165
transcripts that were significantly affected by the defi-
ciency of P2X7 receptors indicating that the deletion of
P2X7 receptors causes genome-wide alterations of gene
expression including depression-related genes in mouse
amygdale (GABAA, GABAC receptors, AMPA and NMDA2B
ionotropic and mGlu5, mGlu7 metabotropic glutamate
receptors were downregulated in KO mice).
Conclusion
These results point to the key role of the endogenous acti-
vation of P2X7 receptors in the level of IL-1β and in the
regulation of individual protein which could be of poten-
tial interest for the study of the neurobiological basis
underlying psychiatric diseases like depression.
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